Clinical trial
A Phase 2,Randomized, Evaluate Efficacy and Safety of Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
NCT04246502 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2,Randomized, Evaluate Efficacy and Safety of Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2020
- Completion date
- December 31, 2024
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic breast cancer